An open study of the safety and efficacy of enoxacin in complicated urinary tract infections

Foot, M.; Williams, Gordon R.; Want, S.; Roe, Maggie; Quaghebeur, G.; Bates, S. A. E.

doi:10.1093/jac/21.suppl_b.97

Cited by 9 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The types of clinical adverse effects (Table 4) were similar to those previously described (23) and were most frequently related to the gastrointestinal tract (nausea, vomiting, abdominal discomfort, diarrhea) or central nervous system (headache, dizziness, sleep disturbance). In two studies, five patients had seizures while receiving enoxacin (18,25). Rashes were uncommon.…”

Section: Clinical Efficacy In Genital Tract Infectionsmentioning

confidence: 99%

Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects

Hooper

Wolfson

1989

Antimicrob Agents Chemother

View full text Add to dashboard Cite

INTRODUCTIONIn the first minireview (66) we considered the activity in vitro, pharmacokinetic properties, and efficacy of fluoroquinolones for the treatment of urinary tract infections and prostatitis. In this minireview we review the role of fluoroquinolones in the treatment of genital infections and summarize the adverse effects of these agents when used for the treatment of genitourinary tract infections.

show abstract

Section: Clinical Efficacy In Genital Tract Infectionsmentioning

confidence: 99%

Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects

Hooper

Wolfson

1989

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…E. faecalis and some combinations thereof) were all eradicated at the end of therapy. However, 48% of patients had relapsed or were reinfected by 4 to 6 weeks after therapy (Foot et al 1988). Huttunen et al (1988) evaluated 67 elderly patients with urinary infections (53 with pyelonephritis, 17 with indwelling catheters) and reported 100% eradication of the infecting organism at the end of treatment with enoxacin 200 or 400mg twice daily for 4 to 14 days.…”

Section: Urinary Tract Infectionsmentioning

confidence: 99%

Clinical Overview of Enoxacin

Zinner

1989

Clinical Pharmacokinetics

View full text Add to dashboard Cite

Enoxacin is a new fluoroquinolone that will be available as oral and intravenous preparations. This drug is bactericida/for a wide range of organisms, including Staphylococcus aureus, S. epidermidis, Enterobacteriaceae and Pseudomonas aeruginosa. In addition, Neisseria gonorrhoeae is exquisitely susceptible. as is Branhamella catarrhal is. The evaluation of the clinical activity of enoxacin is still relatively new. but published studies reveal a good deal of potential in the treatment of infections caused by susceptible bacteria in the urinary tract. upper and lower respiratory tracts. bones and joints. and the gastrointestinal tract. The general use of this drug has been associated with few adverse reactions. Further published data. as well as the results of comparative trials now in progress. will permit a thorough clinical evaluation of this useful drug.Enoxacin (l-ethyl-6-fluoro-l, 4-hydro-4-oxl-7-piperazin-l-yl-I,8-naphthyridine-3-carboxylic acid) is a synthetic antibacterial drug of the fluoroquinolone class. The fluoroquinolones, derivatives of nalidixic acid, have been introduced in the past few years with the promise of broad spectrum antibacterial activity, widespread distribution into tissues and body fluids, favourable pharmacok'inetics and excellent absorption after oral administration. Like other fluoroquinolones, enoxacin is rapidly bactericidal against a broad spectrum of bacteria. Enoxacin shows rapid concentration-dependent bacterial killing (similar to that of the aminoglycosides), with a long postantibiotic effect and activity against organisms in their stationary phase. The mechanism of action of enoxacin is the inhibition of the A-subunit of bacterial DNA gyrase, the enzyme responsible for the negative supercoiling of bacterial DNA.The antibacterial spectrum of enoxacin [defined as including organisms with a minimum inhibitory concentration (MIC) ~ 2.0 mgJL] includes Enterobacteriaceae such as Escherichia coli (MICqo = 0.25 mg/L), Salmonella and Shigella species (MICqo = 0.25 mg/L), Klebsiella and Enterobacter species (MICqo = I mg/L), Proteus species (MICqo = 0.5 mgfL), Serratia marcescens (MICqo = I mg/L), etc.; Pseudomonas aeruginosa (MICqo = 2 mgJL), Yersinia species (MICqo = 0.25 mg/L), Neisseria gonorrhoeae (MICqo = 0.015 mg/L), N. meningitidis (MICqo = 0.06 mgJL), Haemophilus influenzae (MICqo = 0.12 mg/L); Legionella species (MICqo = 0.25 mg/L), Branhamella catarrhalis (MICqo = 0.25 mg/L), methicillin-susceptible Staphylococcus aureus (MICqo = I mg/L), methicillinresistant S. aureus (MICqo = 2 mg/L) and S. epidermidis (MICqo = I mg/L). Other Gram-positive cocci including Streptococcus pneumoniae, S. pyogenes and Enterococcus faecalis (s. faecalis), as well as Listeria monocytogenes, Bacteroidesfragilis and other anaerobic Gram-negative rods, are less susceptible or resistant to enoxacin. In vitro activ-

show abstract

Synthesis of 7‐amino‐1,4‐dihydro‐4‐oxo‐6‐(trifluoromethyl)‐1,8‐naphthyridines. The use of methylidenemalonate as an activating group and a sulfur assisted cyclization

Bridges¹,

Sanchez²

1990

Journal of Heterocyclic Chem

View full text Add to dashboard Cite

2,6‐Dichloro‐3‐(trifluoromethyl)pyridine 3 was used to develop a six‐step preparation of 7‐amino‐4‐oxo‐6‐(trifluoromethyl)naphthyridines. The CF3 group deactivated the pyridine ring towards both nucleophiles and electrophiles. A new reagent for pyridone annulation, the aminomethylidenemalonate anion, is described, along with several strategies to manipulate the electron density of substituted pyridines.

show abstract

An open study of the safety and efficacy of enoxacin in complicated urinary tract infections

Cited by 9 publications

References 0 publications

Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects

Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects

Clinical Overview of Enoxacin

Synthesis of 7‐amino‐1,4‐dihydro‐4‐oxo‐6‐(trifluoromethyl)‐1,8‐naphthyridines. The use of methylidenemalonate as an activating group and a sulfur assisted cyclization

Contact Info

Product

Resources

About